SORM PTO-1449 (modified) Atty. ₩ Client Ref. To: U.S. Department of Commerce Dkt. No. (PW FORM PAT-1449) Patent and Trademark Office 0308678 2002-30-0048A INFORMATION DISCLOSURE STATEME Applicant: BRASLAWSKY et al. BY APPLICANT Appln. No.: 10/796,158 Filing Date: March 10, 2004 Page 1 of Date: April 5, 2004 Examiner: Unassigned Group Art Unit: Unassigned U.S. PATENT DOCUMENTS Examiner's Document Date Name Class Sub Filing Class Date Initials* Number MM/YYYY (Family Name of First Inventor) (if appropriate) 4,485,101 11/1984 AR MMCG Coy BR 4,853,371 08/1989 Coy CR 10/1989 4,871,717 Coy DR 4.904.642 02/1990 Cov 12/1991 ER 5,073,541 Taylor 05/1995 FR 5,411,943 Boaden GR 5,428,019 06/1995 **Edwards** HR 5,597,894 01/1997 Coy IR 5,620,675 04/1997 McBride JR 5,633,263 05/1997 Coy KR 01/1998 5,708,135 Coy LR 5,716,596 02/1998 Dean MR 5,723,578 03/1998 Coy NR 05/1998 5,750,499 Hoeger OR 5,770,687 06/1998 Hornik PR 10/1998 5,820,845 Dean QR 5,830,431 11/1998 Srinivasan RR 6,001,801 12/1999 Coy SR 6,024,938 02/2000 Corbo 08/2001 Albert TR 6,277,356 UR 10/2001 6,307,017 Cov **VR** 6,309,633 10/2001 Ekwuribe MMCdWR 6,465,613 10/2002 English Translation FOREIGN PATENT DOUMENTS Abstract Readily Document Date Country Inventor Name Available MM/YYYY Number Enclosed No Enclose No XR YR OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.) ZR Bakker WH, et al., "Receptor scintigraphy with a radioiodinated somatostatin analogue: radiolabeling, purification, MMCG biologic activity, and in vivo application in animals," J Nucl Med, 1990, 31: 1501-9. **AAR** Behr, TM, et al., "Imaging tumors with peptide-based radioligands," Q J Nucl Med., 2001, 45:189-200. BBR Breeman, WAP, et al., "Studies on radiolabeled somatostatin analogues in rats and in patients," Q J Nucl Med., 1996, 40:209-20. CCR Bruns C, et al., "Molecular pharmacology of somatostatin-receptor subtypes," Ann N Y Acad Sci. 1994, 733; 138-DDR Buscail L, et al., "Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: MMCG mediation by human somatostatin receptor subtypes SSTR1 and SSTR2," Proc Natl Acad Sci U S A, 1994, 91: 2315. Examiner: Date considered: 07/06/2006 /Marcela M Cordero Garcia/

.

		1											
MM	iCG	ÉER	ail L, et al., "Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostate eceptor subtypes SSTR2 and SSTR5 through different mechanisms," Proc Natl Acad Sci U S A, 1995, 92: 158										
		FF	Chattopadhyay S, et al., "Purification and stabilization of 99mTc-d,1-HMPAO: role of organic extractants," Nucl Med Biol, 28:741-744.										
_		GR	Davies N, et al., "Therapeutic potential of octreotide in the treatment of liver metastases," <i>Anticancer Drugs</i> , 1997 7 Suppl 1: 23-31.										
	Н	HR	Decristoforo C, et al., "99m-Technetium-labelled peptide-HYNIC conjugates: effects of lipophilicity and stability obiodistribution," Nucl Med Biol, 1999, 26: 389-96.										
PE	·éy!	R	Dewanjee MK, et al., "Noninvasive imaging of c-myc oncogene messenger RNA with indium-111-antisense prolin a mammary tumor-bearing mouse model," <i>J Nucl Med</i> , 1994, 35: 1054-63.										
2057	ين بس	R	Hammond PJ, et al., "Amino acid infusion blocks renal tubular uptake of an indium-labelled somatostatin analogue," <i>Br J Cancer</i> , 1993, 67: 1437-9.										
	. 5%	KR	Jenkins SA, et al., "Somatostatin analogs in oncology: A look to the future," Chemotherapy, 2001, 47 Suppl 2: 1										
TRADE	LI	_R	Kahan Z, et al., "Inhibition of growth of MX-1, MCF-7-MIII and MDA-MB-231 human breast cancer xenografts affindministration of a targeted cytotoxic analog of somatostatin, AN-238," Int J Cancer, 1999, 82: 592-8.										
	М	MR	Kiaris H, et al., "A targeted cytotoxic somatostatin (SST) analogue, AN-238, inhibits the growth of H-69 small-ce lung carcinoma (SCLC) and H-157 non-SCLC in nude mice," Eur J Cancer, 2001, 37: 620-8.										
	N	NR	Krenning EP, et al., "Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin," Lancet, 1989, 1: 242-4.										
	0	OR	Krenning EP, et al., "Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: Rotterdam experience with more than 1000 patients," <i>Eur J Nucl Med</i> , 1993, 20: 716-31.										
	Р	PR	Kwekkeboom D, et al., "Peptide receptor imaging and therapy," J Nuclear Med, 2000, 41:1704-13.										
	Q	QR	Lee JM, et al., "A somatostatin analogue (SMS 201-995) alters the toxicity of 5-fluorouracil in Swiss mice," Anticancer Res, 1993, 13: 1453-6.										
	R	RR	Nagy A, et al., "Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin its intensely potent derivative, 2-pyrrolinodoxorubiciin," <i>Proc Natl Acad Sci. U.S. A</i> , 1998, 95:1794-99.										
	s	SR	Otte A, et al., "DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy," European J Nucl Med 1997, 24:792-5.										
	Т	TR	Patel YC, et al., "The somatostatin receptor family," Life Sci, 1995, 57: 1249-65.										
	U	UR	Patel YC, "Molecular pharmacology of somatostatin receptor subtypes," J Endocrinol Invest, 1997, 20: 348-67.										
		VR —_	Plonowski A, et al., "Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238," Cancer Res, 1999, 59: 1947-53.										
	V	/WR	Plonowski A, et al., "Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a target cytotoxic analogue of somatostatin AN-238," Cancer Res, 2000, 60: 2996-3001.										
	×	XR	Plonowski A, et al., "Effective treatment of experimental DU-145 prostate cancers with targeted cytotoxic somatostatin analog AN-238," <i>Int J Oncol</i> , 2002, 20: 397-402.										
	Y	YR	Reisine T, et al., "Molecular biology of somatostatin receptors," Endocr Rev, 1995, 16: 427-42.										
	z		Reubi JC, et al., "Somatostatin receptors in human prostate and prostate cancer," J Clin Endocrinol Metab, 199 80: 2806-14.										
	A	AAR	Reubi JC, et al., "Somatostatin receptors and their subtypes in human tumors and in peritumoral vessels," Metabolism, 1996, 45: 39-41.										
	В	BBR	Sagiuchi T, et al., "Transient seizure activity demonstrated by Tc-99m HMPAO SPECT and diffusion-weighted Nimaging," <i>Ann Nucl Med</i> , 2001, 15: 267-70.										
	С	CCR	Smith-Jones PM, et al., "Synthesis, biodistribution and renal handling of various chelate-somatostatin conjugate with metablolizable linking groups," Nuc Med Biol, 1997, 24:761-69.										
	D	DDR	Smith-Jones PM, et al., "Synthesis and characterisation of [90Y]-Bz-DTPA-oct: A Yttrium-90-Labelled octreotide analogue for radiotherapy of somatostatin receptor-positive tumours," Nuc Med Biol, 1998, 25:181-8.										
	E	EER	Srkalovic G, et al., "Evaluation of receptors for somatostatin in various tumors using different analogs," <i>J Clin Endocrinol Metab</i> , 1990, 70: 661-9.										
	F	FFR	Stewart GJ, et al., "Octreotide inhibits development of hepatic metastases from a human colonic cancer cell line Br J Surg, 1994, 81: 1332.										
	G	GGR	Szepeshazi K, et al., "Targeting of cytotoxic somatostatin analog AN-238 to somatostatin receptor subtypes and/or 3 in experimental pancreatic cancers," Clin Cancer Res, 2001, 7: 2854-81.										
	Н	HHR	Virgolini I, et al., "New trends in peptide receptor radioligands," Q J Nucl Med, 2001, 45:153-9.										
$\underline{\Psi}$	111	R	Weckbecker G, et al., "Somatostatin analogs for diagnosis and treatment of cancer," <i>Pharmacol Ther</i> , 1993, 60: 245-64.										
MM	CG J	JJR	Yoo TM, et al., "Technetium-99m labeling and biodistribution of anti-TAC disulfide-stabilized Fv fragment," <i>J Numbed</i> , 1997, 38: 294-300.										
xamine	r	1	Marcela M Cordero Garcia/ Date Considered: 07/06/2006										

PAN 1 C						30174		Atty. Dkt. No.	M#	√I#			Client Ref.					
			P		• • •	2 3)		037003	030	8678		200)2-3(0-0	048A			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT									Applicant: BRASLAWSKY et al.									
DI AFFEI	OAIII							Appln. No	o.: 1	0/796,158						_		
								Filing Date: January 11, 2005										
Date: January 11, 2005 Page 1						1		Examiner: Unassigned Group Art Unit: 161								16		
U.S. PATE			,			' 								_				
Examiner's Initials*	xaminer's Document		ocument ·		YYYY	Name (Family Name		of First Inventor)		Clas		Sub Class		Filing Date (if appropriate				
MMC	AR	US2002/009	4964	07/2	002	Chen				·	1-				(п арргор	11010		
MMCG		US2003/009		05/2		McBride									-			
MMCG	CR																	
	DR					1												
	ER			1														
	FR																	
	GR																	
	HR																	
	IR																	
	JR																	
	KR						-											
	LR			<u> </u>														
	MR					1								_				
	NR	<u> </u>												_				
	OR			ļ										_				
ļ	PR			ļ		ļ								_				
	QR			ļ		ļ								ᆜ				
	RR	<u> </u>]		<u> </u>												
FOREIGN F	PATEN	T DOUMENT	<u>s</u>									English			Translat	ion		
		Document Date Number MM/Y		Count		try Inve		ntor Name	•			Abstrac			Readily Available			
			 		ļ		1	<u> </u>				Enclose	d No	긔	Enclose	1NC		
	SR	· · · · · · · · · · · · · · · · · · ·	┼—		-		-					 	+	-		+		
	TR		 		+		 					+	+	\dashv		+		
ļ	UR	 	 				┼	-				 	+			╀		
	VR	 	 						\dashv				+			╀		
	WR	<u> </u>	<u> </u>		<u> </u>		<u> </u>					 	┿	ᆛ		╄		
MMCG	cluding XR	in this order A									ару," Е	Biopolyn	 ners	 (P	eptide	<u></u>		
		Science), 20	02, 66:	161-	183.													
	YR	ļ																
<u> </u>	ZR							· · · · · · · · · · · · · · · · · · ·										
	AAR	 			-			. -										
	BBR	 										,						
	CCR																	
Examiner		rcela M Co								red: 07/06				_				
in conforman	. Initial ce and	if citation consi not considered	idered, Includ	wheth e copy	er or no	ot citation is form with i	next co	ntormance ommunicati	with I	MPEP § 609. Applicant.	Draw l	ine thro	ngh c	cita	tion if n	ot		